ALTACE

LOE ApproachingSM

ramipril

NDAORALTABLET
Approved
Feb 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

animals. Angiotensin converting enzyme is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased plasma angiotensin II,…

Clinical Trials (5)

NCT04366050Phase 2Completed

Ramipril for the Treatment of COVID-19

Started May 2020
160 enrolled
COVID-19
NCT03715998Phase 2Completed

Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction

Started Jun 2019
295 enrolled
Myocardial Infarction
NCT03414723Phase 1Completed

A Drug-Drug Interaction Study Between Sotagliflozin and Ramipril

Started Jan 2018
16 enrolled
Diabetes MellitusHealthy Subjects
NCT02499822Phase 4Completed

REducing Blood Pressure Variability in Essential Hypertension With RAmipril vErsus Nifedipine GITS Trial

Started Oct 2015
168 enrolled
HypertensionHigh Blood Pressure Variability
NCT01284621Phase 1Completed

Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy Volunteers

Started Jan 2011
23 enrolled
Healthy